Skip to main content

Table 2 Baseline and change from baseline in liver volume during up to 24 months of miglustat therapy (primary analysis)

From: Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study

  Non-splenectomized Splenectomized All
  (N = 23) (N = 9) (N = 32)
Baseline absolute value (mL)    
 Mean ± SD 1742 ± 440 1857 ± 604 1775 ± 484
End of treatment absolute value (mL)    
 Mean ± SD 1736 ± 353 1704 ± 470 1727 ± 382
Absolute change from baseline (mL)    
 Mean −6.4 −152.6 −47.5
 95% CI (−124, 111) (−395, 90) (−151, 56)
Percent change from baseline    
 Mean 1.3 −7.2 −1.1
 95% CI (−4.6%, 7.3%) (−16.6%, 2.2%) (−6.0%, 3.9%)
  1. Data analysis based on full analysis population.